摘要
乳腺癌作为女性最常见的恶性肿瘤,受到多种因素共同调节。泛素-蛋白酶体系统失调与乳腺癌发病和进展密切相关。其中,作为去泛素化酶家族的主要成员,泛素特异性蛋白酶(ubiquitin-specific proteases,USPs)大多在乳腺癌中过度表达,已成为乳腺癌疾病研究的潜在治疗靶点。目前,已有很多学者将USPs分子的靶向抑制剂研发作为乳腺癌抗癌药物研究的重要方向。本文总结了USPs不同成员在乳腺癌增殖、凋亡、迁移、药物疗效等进程中的进展,同时汇总了USPs靶向抑制剂的研发情况,以及抑制剂对乳腺癌的作用效果及机制,为开发疗效更好、选择性更佳的临床候选药物提供参考。
Breast cancer,as the most common malignancy in women,is regulated by multiple factors.Dysregulation of the ubiquitin-proteasome system has been reported to be closely associated with breast cancer pathogenesis and progression.Among them,ubiquitin-specific proteases,as the main members of the deubiquitinating enzyme family,are mostly overexpressed in breast cancer and have become potential therapeutic targets for breast cancer disease research.At present,many scholars have taken targeted inhibitors of USPs molecules as an important direction for exploring anticancer drugs for breast cancer.In this paper,we summarized the research progress of different members of USPs in breast cancer proliferation,apoptosis,migration,and drug efficacy.Besides,the research and development of USPs targeted inhibitors are summarized,as well as the effect and mechanism of inhibitors on breast cancer,providing a reference for the discovery of clinical candidates with better efficacy and selectivity.
作者
黄美玲
李南林
HUANG Meiling;LI Nanlin(Department of Thyroid,Breast and Vascular Surgery,Xijing Hospital,Air Force Military Medical University,Xi'an 710032,China)
出处
《生命的化学》
CAS
2022年第11期1996-2003,共8页
Chemistry of Life
基金
国家自然科学基金项目(81472598)
空军军医大学西京医院助推项目(XJZT18MJ30)。
